Innospec Announces Opening Of Personal Care Specialty Chemicals Ester Plant At Ellesmere Port, U.K.
Newark, DE - Innospec Inc. announced the commissioning of a new specialty chemicals processing plant at its Ellesmere Port site in the U.K. to produce ester for the global personal care products market. Built in eight months at a total cost of approximately $1.2 million, the plant started up last month producing Finsolv TN(r), an ester that to date has been manufactured at Innospec's plant in Spencer, NC.
One of the purposes for building this new ester plant in the U.K. is to save considerable costs on freight and shorten the supply chain, enabling the company to more efficiently serve personal care products customers outside the U.S., as more demand arises from customers currently importing Finsolv TN from the U.S., and from new global buyers for other esters that can be manufactured at Ellesmere Port.
"The opening of our new plant is a key step forward toward our objective of making this division a truly global business, thereby reinforcing our status as a world-leading specialty chemicals company," noted Paul Jennings, Innospec President and Chief Executive Officer. "This highlights our strong commitment to the specialty personal care chemicals segment of our business and its promising growth prospects."
The new plant at Ellesmere Port complements other Innospec specialty performance chemicals manufacturing facilities in Europe dedicated to supplying the global personal care products market. Notable among these is Innospec's aroma manufacturing plant for Lilestralis(r) in Widnes, Cheshire, UK. Lilestralis is used extensively in many different perfumery applications, especially in fabric softeners, soaps and other personal care products.
Innospec's personal care business has annual global sales of about $35 million, including its sales of Finsolv TN, with a strong technology and manufacturing base and a history of developing successful new processes and esters for the personal care products industry in-house.
SOURCE: Innospec Inc.